Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

Alessia Biolchi, Sara Tomei, Laura Santini, Jo Anne Welsch, Daniela Toneatto, Nikolaos Gaitatzis, Xilian Bai, Raymond Borrow, Marzia Monica Giuliani, Elena Mori, Mariagrazia Pizza*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effectiveness of 82.9%. Here we compared the coverage of two 4CMenB vaccination schedules (3 + 1 [2.5, 3.5, 5, 11 months] versus 2 + 1 [3.5, 5, 11 months of age]) against 40 serogroup B strains, representative of epidemiologically-relevant isolates circulating in England and Wales in 2007–2008, using sera from a previous phase 3b clinical trial. The strains were tested using hSBA on pooled sera of infants, collected at one month post-primary and booster vaccination. 4CMenB coverage was defined as the percentage of strains with positive killing (hSBA titres ≥ 4 after immunisation and negative baseline hSBA titres < 2). Coverage of 4CMenB was 40.0% (95% confidence interval [CI]: 24.9–56.7) and 87.5% (95%CI: 73.2–95.8) at one month post-primary and booster vaccination, respectively, regardless of immunisation schedule. Using a more conservative threshold (post-immunisation hSBA titres ≥ 8; baseline ≤ 2), at one month post-booster dose, strain coverages were 80% (3 + 1) and 70% (2 + 1). We used a linear regression model to assess correlation between post-immunisation hSBA data for each strain in the two groups; Pearson’s correlation coefficients were 0.93 and 0.99 at one month post-primary and booster vaccination. Overall, there is no evidence for a difference in strain coverage when 4CMenB is administered according to a 3 + 1 or 2 + 1 infant vaccination schedule.

Original languageEnglish
Pages (from-to)725-731
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume15
Issue number3
DOIs
Publication statusPublished - 4 Mar 2019

Bibliographical note

Publisher Copyright:
© 2018, © 2018 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC.

Keywords

  • 4CMenB vaccine
  • infant immunisation schedule
  • meningococcal serogroup B
  • pooled sera
  • serum bactericidal antibody assay
  • strain coverage

Fingerprint

Dive into the research topics of 'Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules'. Together they form a unique fingerprint.

Cite this